期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 99, 期 -, 页码 52-69出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2015.12.024
关键词
-
资金
- Department of Defense Prostate Cancer Idea award [W81XWH-12-1-0406]
- American Heart Association National Scientist Award [14SDG18690009]
- National Heart, Lung, and Blood Institute of National Institutes of Health (NIH) [R56HL121392]
- National Institute of Neurological Disorders and Stroke of NIH [R01NS093314]
Mitochondrial dysfunctions are recognized as major factors for various diseases including cancer, cardiovascular diseases, diabetes, neurological disorders, and a group of diseases so called mitochondrial dysfunction related diseases. One of the major hurdles to gain therapeutic efficiency in diseases where the targets are located in the mitochondria is the accessibility of the targets in this compartmentalized organelle that imposes barriers toward internalization of ions and molecules. Over the time, different tools and techniques were developed to improve therapeutic index for mitochondria acting drugs. Nanotechnology has unfolded as one of the logical and encouraging tools for delivery of therapeutics in controlled and targeted manner simultaneously reducing side effects from drug overdose. Tailor-made nanomedicine based therapeutics can be an excellent tool in the toolbox for diseases associated with mitochondrial dysfunctions. In this review, we present an extensive coverage of possible therapeutic targets in different compartments of mitochondria for cancer, cardiovascular, and mitochondrial dysfunction related diseases. (C) 2016 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据